Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Toni K ChoueiriPiotr TomczakSe Hoon ParkBalaji VenugopalThomas FergusonYen-Hwa ChangJaroslav HajekStefan N SymeonidesJae Lyun LeeNaveed SarwarAntoine Thiery-VuilleminMarine Gross-GoupilMauricio MahaveNaomi B HaasPiotr SawryckiHoward GurneyChristine ChevreauBohuslav MelicharEvgeniy KopyltsovAjjai AlvaJohn M BurkeGurjyot DoshiDelphine TopartStephane OudardHans HammersHiroshi KitamuraJens BedkeRodolfo F PeriniPingye ZhangKentaro ImaiJaqueline Willemann-RogerioDavid I QuinnThomas Powlesnull nullPublished in: The New England journal of medicine (2021)
Pembrolizumab treatment led to a significant improvement in disease-free survival as compared with placebo after surgery among patients with kidney cancer who were at high risk for recurrence. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.).